Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites.

Acta pharmacologica Sinica - 1 Apr 2019

Bai Xue, Zhang Bin, Wang Ping, Wang Guan-Lei, Li Jia-Li, Wen Ding-Sheng, Long Xing-Zhen, Sun Hong-Shuo, Liu Yi-Bin, Huang Min, Zhong Shi-Long

Abstract excerpt

Myotoxicity is a significant factor contributing to the poor adherence and reduced effectiveness in the treatment of statins. Genetic variations and high drug plasma exposure are considered as critique causes for statin-induced myopathy (SIM). This study aims to explore the sequential influences of rosuvastatin (RST) pharmacokinetic and myopathy-related single-nucleotide polymorphisms (SNPs) on the plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to China
Share to Coronary Artery Disease

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ABCG2 gene

Share to Genetic Variation

Share to Liver-Specific Organic Anion Transporter 1

Share to Muscular Diseases

Share to Polymorphism, Single Nucleotide

Share to Rosuvastatin Calcium

Source

Open in PubMed Open full text

Identifiers

PMID: 29950617
DOI: 10.1038/s41401-018-0013-y
PMCID: PMC6461793

Genes

GATM
ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites.PMID 29950617Read ↗

The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis.Semantic proximity Read ↗

Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.Semantic proximity Read ↗

Genetic Determinants of Statin-induced Myopathy: A Network Meta-analysis of Observational Studies.Semantic proximity Read ↗

Pharmacogenomic insights into treatment and management of statin-induced myopathySemantic proximity Read ↗

The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study.Semantic proximity Read ↗

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle ComponentsSemantic proximity Read ↗

Genetic Polymorphisms in Drug Transporter Genes (ABCB1, OATP1B1) and Their Impact on Statin Pharmacokinetics and Myopathy RiskSemantic proximity Read ↗

Pharmacogenetics of Statin-Induced MyotoxicitySemantic proximity Read ↗

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.Semantic proximity Read ↗

The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence.Semantic proximity Read ↗

GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals.Semantic proximity Read ↗

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.